-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
ZIVO Bioscience (OTCMKTS:ZIVO) Share Price Passes Below 50-Day Moving Average of $3.65
ZIVO Bioscience (OTCMKTS:ZIVO) Share Price Passes Below 50-Day Moving Average of $3.65
ZIVO Bioscience, Inc. (OTCMKTS:ZIVO – Get Rating) passed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $3.65 and traded as low as $2.85. ZIVO Bioscience shares last traded at $3.02, with a volume of 6,150 shares traded.
ZIVO Bioscience Price Performance
The business's 50-day moving average price is $3.62 and its two-hundred day moving average price is $3.55. The company has a market capitalization of $26.38 million, a P/E ratio of -2.83 and a beta of -0.05.
Get ZIVO Bioscience alerts:ZIVO Bioscience (OTCMKTS:ZIVO – Get Rating) last issued its quarterly earnings data on Thursday, August 4th. The biotechnology company reported ($0.22) EPS for the quarter.
Insider Transactions at ZIVO Bioscience
In other ZIVO Bioscience news, Director Christopher D. Maggiore bought 7,200 shares of the firm's stock in a transaction that occurred on Wednesday, September 14th. The shares were acquired at an average cost of $3.53 per share, with a total value of $25,416.00. Following the acquisition, the director now owns 810,305 shares of the company's stock, valued at $2,860,376.65. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 9.10% of the company's stock.Institutional Investors Weigh In On ZIVO Bioscience
A hedge fund recently raised its stake in ZIVO Bioscience stock. Vanguard Group Inc. grew its position in ZIVO Bioscience, Inc. (OTCMKTS:ZIVO – Get Rating) by 19.6% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 92,468 shares of the biotechnology company's stock after purchasing an additional 15,147 shares during the quarter. Vanguard Group Inc. owned approximately 0.98% of ZIVO Bioscience worth $359,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 5.04% of the company's stock.
About ZIVO Bioscience
(Get Rating)
ZIVO Bioscience, Inc, a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. It operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health.
See Also
- Get a free copy of the StockNews.com research report on ZIVO Bioscience (ZIVO)
- 2 Casino Stocks Worth Taking a Look At
- This Small-Cap Healthcare Name Is Outperforming Its Index
- What Cintas Can Teach Investors About This Bear Market?
- Blackberry Stock Declines As Results Come In Lukewarm Once Again
- A Trio of Q3 Winners With Room to Run
Receive News & Ratings for ZIVO Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIVO Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
ZIVO Bioscience, Inc. (OTCMKTS:ZIVO – Get Rating) passed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $3.65 and traded as low as $2.85. ZIVO Bioscience shares last traded at $3.02, with a volume of 6,150 shares traded.
Zivo Bioscience，Inc.(場外交易市場代碼：Zivo-GET評級)在週二的交易中跌破了50日移動均線。該股的50日移動均線為3.65美元，最低交易價格為2.85美元。Zivo Bioscience的股票最新報3.02美元，成交量為6,150股。
ZIVO Bioscience Price Performance
Zivo生物科學性價比
The business's 50-day moving average price is $3.62 and its two-hundred day moving average price is $3.55. The company has a market capitalization of $26.38 million, a P/E ratio of -2.83 and a beta of -0.05.
該業務的50日移動均線價格為3.62美元，200日移動均線價格為3.55美元。該公司市值為2,638萬美元，市盈率為-2.83，貝塔係數為-0.05。
ZIVO Bioscience (OTCMKTS:ZIVO – Get Rating) last issued its quarterly earnings data on Thursday, August 4th. The biotechnology company reported ($0.22) EPS for the quarter.
Zivo Bioscience(OTCMKTS：ZIVO-GET Rating)最近一次發佈季度收益數據是在8月4日星期四。這家生物技術公司公佈了本季度每股收益(0.22美元)。
Insider Transactions at ZIVO Bioscience
Zivo Bioscience的內幕交易
Institutional Investors Weigh In On ZIVO Bioscience
機構投資者看好Zivo生物科學
A hedge fund recently raised its stake in ZIVO Bioscience stock. Vanguard Group Inc. grew its position in ZIVO Bioscience, Inc. (OTCMKTS:ZIVO – Get Rating) by 19.6% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 92,468 shares of the biotechnology company's stock after purchasing an additional 15,147 shares during the quarter. Vanguard Group Inc. owned approximately 0.98% of ZIVO Bioscience worth $359,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 5.04% of the company's stock.
一家對衝基金最近增持了Zivo Bioscience股票。先鋒集團(Vanguard Group Inc.)在最近提交給美國證券交易委員會的13F文件中稱，今年第一季度，該公司在Zivo Bioscience，Inc.(場外交易代碼：Zivo-GET評級)的持倉增加了19.6%。該基金在本季度額外購買了15,147股後，持有這家生物技術公司的92,468股股票。截至最近提交給美國證券交易委員會的文件，先鋒集團持有Zivo Bioscience約0.98%的股份，價值35.9萬美元。機構投資者和對衝基金持有該公司5.04%的股票。
About ZIVO Bioscience
關於Zivo生物科學
(Get Rating)
(獲取評級)
ZIVO Bioscience, Inc, a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. It operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health.
Zivo Bioscience，Inc.是一家研發公司，致力於向動物、人類、膳食補充劑和醫用食品製造商許可和銷售從其專有藻類培養物中提取的天然生物活性成分。它在生物技術和農業技術部門開展業務，擁有知識產權組合，包括專有藻類和細菌菌株、生物活性分子和複合體、生產技術、栽培技術，以及應用於人類和動物健康的專利或正在申請專利的發明。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on ZIVO Bioscience (ZIVO)
- 2 Casino Stocks Worth Taking a Look At
- This Small-Cap Healthcare Name Is Outperforming Its Index
- What Cintas Can Teach Investors About This Bear Market?
- Blackberry Stock Declines As Results Come In Lukewarm Once Again
- A Trio of Q3 Winners With Room to Run
- 免費獲取StockNews.com關於Zivo生物科學的研究報告(Zivo)
- 值得一看的2只賭場股票
- 這家小盤股醫療保健公司的表現好於其指數
- 關於這個熊市，Cintas能教給投資者什麼？
- 黑莓股價下跌，業績再次不温不火
- 第三季度贏家三人組還有運行的空間
Receive News & Ratings for ZIVO Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIVO Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
獲得Zivo生物科學日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Zivo Bioscience和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧